Recent News

• 01.22.2026 - Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
• 01.21.2026 - Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
• 01.14.2026 - Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
• 01.08.2026 - Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
• 12.11.2025 - Plus Therapeutics Expands CNSide Assay Platform to State of California
• 12.09.2025 - Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
• 12.09.2025 - December 9, 2025 - December 12, 2025 : San Antonio Breast Cancer Symposium
• 12.09.2025 - December 9, 2025 - December 12, 2025 : San Antonio Breast Cancer Symposium
• 12.04.2025 - Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
• 12.01.2025 - Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Recent Filings

• 01.16.2026 - 8-K Current report
• 01.16.2026 - EX-99.1 EX-99.1
• 01.14.2026 - 424B4 Prospectus [Rule 424(b)(4)]
• 01.13.2026 - S-1MEF Registration adding securities to prior Form S-1 registration [Rule 462(b)]
• 01.13.2026 - EFFECT Notice of Effectiveness
• 01.09.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 01.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.25.2025 - DRS Draft Registration Statement